Cellectar Biosciences Inc (NASDAQ:CLRB)’s traded shares stood at 14.58 million during the last session, with the company’s beta value hitting 0.55. At the close of trading, the stock’s price was $0.43, to imply an increase of 16.64% or $0.06 in intraday trading. The CLRB share’s 52-week high remains $3.42, putting it -695.35% down since that peak but still an impressive 48.84% since price per share fell to its 52-week low of $0.22.
Analysts have given a consensus recommendation of Buy for Cellectar Biosciences Inc (CLRB), translating to a mean rating of 2.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CLRB a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.
Cellectar Biosciences Inc (NASDAQ:CLRB) trade information
After registering a 16.64% upside in the last session, Cellectar Biosciences Inc (CLRB) has traded red over the past five days. The 5-day price performance for the stock is -7.56%, and 61.61% over 30 days. With these gigs, the year-to-date price performance is 42.74%.
The extremes give us $12 and $12 for target low and target high price respectively. As such, CLRB has been trading -2690.7% off suggested target high and -2690.7% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 40.27% for the past 5-year period. While 2025 is set for a 55.21% return in earnings, projections for the next 5 years are at 24.38% annually.
CLRB Dividends
Cellectar Biosciences Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is ROSALIND ADVISORS, INC. with 2.71 million shares, or about 7.5535% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $6.76 million.
